TeselaGen, JBEI Renew Biomanufacturing Partnership

September 29, 2023

TeselaGen Biotechnology and the Department of Energy’s Joint BioEnergy Institute (JBEI) have renewed their partnership with a five-year contract to advance biofuels and bioproducts research. TeselaGen’s AI-powered platform aids in developing renewable biofuels from nonfood plant fibers. This extended collaboration will focus on enhancing workflow capabilities and furthering sustainable biological production. TeselaGen continues to foster multiple partnerships, contributing to the growth of the U.S. bioeconomy.

TeselaGen’s AI-powered platform enables biotech innovation to happen faster and at scale

September 20, 2023

In the heart of Miami’s tech revolution, a remarkable force is reshaping the landscape – TeselaGen. This cutting-edge startup, led by founder and CEO Eduardo Abeliuk, is at the forefront of AI-driven biotech innovation. With a platform designed to empower biotech R&D professionals, TeselaGen is propelling research to new heights of speed and scalability, regardless of the specific field – from agritech to gene therapy. Their mission is clear: to democratize access to advanced scientific tools and algorithms, with the ultimate goal of making TeselaGen a household name in the world of biology within the next five years.

On Biotech Engineering and AI: a Conversation with TeselaGen’s CEO, Eduardo Abeliuk

July 18, 2023

Navigating the dynamic intersection of biology and data science, Eduardo Abeliuk, the CEO of TeselaGen Biotechnology, invites us on a journey through his career and his company’s role in the biotechnology industry. Abeliuk’s roots in computational biology research at Stanford University and his rich background as a founder, advisor, board member, and investor have collectively sculpted the robust ethos of TeselaGen.

From Gene Editing to Pathway Design: How AI is Transforming Synthetic Biology

July 18, 2023

Biotechnology has the potential to address some of the most pressing challenges of the 21st century. AI is playing a crucial role in advancing synthetic biology by facilitating the design, construction, and optimization of biological systems.

Eduardo Abeliuk Of Teselagen On The Future Of Artificial Intelligence: An Interview With David Leichner

April 17, 2023

Dr. Eduardo Abeliuk is a U.S. based entrepreneur and technologist with over twenty years of experience driving technology development and innovation at various high-tech companies in the US. He is currently the Chairman and CEO at TeselaGen Biotech., a Silicon Valley based company that works at the interface between Biotechnology, Artificial Intelligence and Enterprise Software.

AI-Enabled Design-and-Test platform speeds bioproduct development

May 1, 2021

TeselaGen Biotechnology (San Francisco, Calif.; www.teselagen.com) has developed a platform technology that integrates software and services, while taking advantage of artificial intelligence (AI) by applying machine-learning algorithms to reduce the costs and time required for the development of biologically derived products. “Among the main challenges in biotechnology is that developing bioproducts can take years and cost millions of dollars,” says Eduardo Abeliuk, CEO of TeselaGen. “We think of ourselves as an operating system for biotech that allows the end-to-end integration of different AI-enabled software modules with other product development services.” As an analogy, Abeliuk likens the way his company’s platform works

Make life better™

News & Press